<< Back

Press Release

November 1, 2017 at 4:05 PM EDT

Innoviva to Participate at the Credit Suisse and Stifel Annual Healthcare Conferences in November

BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017:

Credit Suisse 26th Annual Healthcare Conference
November 8, 2017 at 12:20 pm MT
Scottsdale, Arizona
To view the webcast follow this link: INVA at Credit Suisse

Stifel Nicolaus Weisel 2017 Healthcare Conference
November 15, 2017 at 10:15 a.m. ET
New York, NY
To view the webcast follow this link: INVA at Stifel

Both presentations will be available and archived on the investor relations page of the Innoviva web site at: http://investor.inva.com/events.cfm.

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for TRELEGY® ELLIPTA® and earlier-stage programs partnered with Theravance BioPharma, Inc.. For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief Financial Officer

Source: Innoviva, Inc.

News Provided by Acquire Media


Copyright West LLC. Minimum 15 minutes delayed.


Innoviva Investor Relations & Media

For business development inquiries,
please contact bd@inva.com.